Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial [0.03%]
TALAPRO-2试验中塔拉唑帕利联合恩杂鲁胺治疗转移性去势抵抗性前列腺癌(mCRPC)的暴露安全分析
Yibo Wang,Mark Hadigol,Victor Ruberio Lincha et al.
Yibo Wang et al.
The TALAPRO-2 trial (NCT03395197) showed that the addition of talazoparib, a potent PARP inhibitor, to enzalutamide significantly improved radiographic progression-free survival in patients with mCRPC. Due to adverse events (AEs), approxima...
Development of a novel rabeprazole modified release formulation to reduce the dosing frequency: A trial and triumph with physiologically based biopharmaceutics modeling [0.03%]
基于生理的生物药剂学模型减少剂量频率的新一代埃索美拉唑缓释制剂的研发：尝试与成功
Harika Maddukuri,Rajkumar Boddu,Sangmesh Mallikarjun Chaudhari et al.
Harika Maddukuri et al.
Advanced in silico tools, such as physiologically based biopharmaceutics models (PBBM) and physiologically based pharmacokinetic models (PBPK), play a pivotal role in model-informed formulation development (MIFD). In the present study, thes...
Randomized Controlled Trial
Journal of pharmacokinetics and pharmacodynamics. 2026 May 16;53(4):25. DOI:10.1007/s10928-026-10035-w 2026
Multi-objective optimization in population pharmacokinetic model selection and optimization: application of NSGA-II in pyDarwin [0.03%]
群体药代动力学模型选择与优化的多目标优化：pyDarwin中NSGA-II算法的应用
Xinnong Li,Mark Sale,James Craig et al.
Xinnong Li et al.
The selection of a "good" model usually involves a combination of objective and subjective criteria. Although many aspects of model quality can be expressed numerically, certain desirable characteristics remain difficult-or even impossible-...
Adaptive PK/PD model optimization: a comparative analysis of bounded optimization methods for individual BIS prediction [0.03%]
适应性PK / PD模型优化：个别BIS预测的有界优化方法的比较分析
Zheyan Tu,Sean Jeffries,Eric Pelletier et al.
Zheyan Tu et al.
Tracer kinetic modeling of a 14 kDa anti-CD8 PET tracer (2C8v144) for in vivo estimation of CD8 expression in tissue and blood, binding affinity, and total body receptor occupancy [0.03%]
一种针对CD8的PET示踪剂（2C8v144）的追踪动力学建模，用于体内估算组织和血液中的CD8表达、结合亲和力以及全身受体占有率
Ruediger E Port,C Andrew Boswell,Annie Ogasawara et al.
Ruediger E Port et al.
J Alexander Gilsoul,Hwai-Ray Tung,Sean D Lawley
J Alexander Gilsoul
A structure-preserving hybrid learning framework for compartmental pharmacokinetic models [0.03%]
一种用于隔室药代动力学模型的结构保持型混合学习框架
Hanan Al Lawati,Mohamed Al-Lawatia
Hanan Al Lawati
Development of a population pharmacokinetics model and an R-Shiny simulation platform for moxifloxacin pharmacokinetics in non-human primates [0.03%]
用于非人灵长类动物莫西沙星药代动力学的群体药代动力学模型及R-Shiny模拟平台的开发
Arnay Garhyan,Derek Leishman
Arnay Garhyan
A hybrid PKPD agent-based model of the tumour immune interaction: effects of anti-cancer combination therapy [0.03%]
一种肿瘤免疫作用的混合PKPD代理模型：抗癌症联合疗法的影响
Van Thuy Truong,Grant Lythe,Paolo Vicini et al.
Van Thuy Truong et al.
We have developed a three dimensional hybrid multiscale agent-based ODE PDE model including tumour immune interaction, cell cycle phases, oxygen and drug diffusion dynamics, the pharmacodynamics of chemotherapy, targeted therapies, immunoth...